| Literature DB >> 27900667 |
Luc M Hondeghem1, Noël H Logghe2.
Abstract
Domperidone has been used as a galactagogue; however, solid evidence from an adequate sized randomized clinical trial is missing. Optimal dosage, start of treatment, length of treatment and scope of patients who can benefit also remain unknown. Although milk obtained after domperidone administration has not been shown to have untoward effects on newborns, no sufficiently large randomized clinical trial has been done to establish safety. Domperidone has repeatedly been shown to produce sudden cardiac death, starting at 30 mg/day. Because of this known cardiac effect, the use of domperidone to increase breast milk production may not be justified.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27900667 DOI: 10.1007/s40264-016-0478-x
Source DB: PubMed Journal: Drug Saf ISSN: 0114-5916 Impact factor: 5.606